Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

21 evidence topics · 14 sources

Descartes-08: AChR antibody-positive subgroup, MGC response at month 3, mITT population (phase 2b)
Descartes-08: biologic-naive versus biologic-exposed participants, post hoc analysis, mITT population (phase 2b)

“A post hoc analysis was conducted to evaluate the magnitude of response to Descartes-08 in participants who were biologic-naive and those with prior biologic exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants with no prior exposure to complement inhibitors, FcRn inhibitors or CD19/CD20-targeting monoclonal antibodies (biologic-naive) demonstrated an improved response to Descartes-08 compared to those with prior biologic exposure, with 55.6% (n = 5/9) of participants achieving MSE by month 6, which was maintained through month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Additionally, the biologic-naive group had a greater proportion of MGC responders at month 3 compared to the group with prior biologic exposure (88.9% versus 33.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were also notable reductions in MG severity scores from baseline to month 3 for the biologic-naive group versus those with prior biologic exposure (mean (s.d.) score: MGC −7.7 (5.24) versus 1.0 (6.96); MG-ADL −5.2 (3.27) versus −2.5 (3.08); QMG −5.0 (3.84) versus −2.2 (4.92)), with scores further improved by month 12 (MGC −11.0 (4.0), MG-ADL −7.1 (1.9), QMG −9.4 (2.6)) (Extended Data Table 5 and Extended Data Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Notably, 100.0% of biologic-naive participants maintained at least a clinically meaningful response at month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Biologic-exposed participants were non-responders to prior FcRn or complement inhibitor treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Inebilizumab effect by antibody status
Week 26 outcomeOverall populationAnti-AChR antibody positiveAnti-MuSK antibody positive
MG-ADL difference from placebo“-1.9”“-1.8”“-2.2”
MG-ADL p-value“<0.0001”“0.0015”“0.0297”
QMG difference from placebo“-2.5”“-2.5”“-2.3”
QMG p-value“0.0002”“0.0011”“NS”